{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:13:20Z","timestamp":1785791600085,"version":"3.56.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1173061","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:40:22Z","timestamp":1683261622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice"],"prefix":"10.3389","volume":"14","author":[{"given":"Ruoyao","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangtao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/pathogens10111440","article-title":"Sustained antiviral and liver protection by a nasal therapeutic vaccine (NASVAC, containing both HBsAg and HBcAg) in patients with chronic hepatitis B: 2-year follow-up of phase III clinical trial","volume":"10","author":"Akbar","year":"2021","journal-title":"Pathogens"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/jvh.13483","article-title":"Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy","volume":"28","author":"Bazinet","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \"New\" Antigen in Leukemia Sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/HMER.S291976","article-title":"Current perspectives on Nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus","volume":"14","author":"Broquetas","year":"2022","journal-title":"Hepat. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2012.05.009","article-title":"Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors","volume":"57","author":"Huang","year":"2012","journal-title":"J. Hepatol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"ref7","first-page":"578","article-title":"Construction and application of an Escherichia coli high effective expression vector with an enhancer","volume":"16","author":"Luo","year":"2000","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"100361","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/v12080851","article-title":"Advances with RNAi-based therapy for hepatitis B virus infection","volume":"12","author":"van den Berg","year":"2020","journal-title":"Viruses"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"32ra35","DOI":"10.1126\/scitranslmed.3001143","article-title":"Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription","volume":"2","author":"Wu","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3748\/wjg.v11.i4.492","article-title":"Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus","volume":"11","author":"Yang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/gutjnl-2018-317725","article-title":"A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice","volume":"69","author":"Zhang","year":"2020","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/21645515.2015.1009343","article-title":"Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment","volume":"11","author":"Zhang","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molimm.2020.12.004","article-title":"Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA\/cas9 produces a synergistic antiviral effect in HBV infection","volume":"130","author":"Zhen","year":"2021","journal-title":"Mol. Immunol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1173061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:40:25Z","timestamp":1683261625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1173061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":18,"alternative-id":["10.3389\/fmicb.2023.1173061"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1173061","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1173061"}}